EGFR T790M: Revealing the secrets of a gatekeeper

Brian Ko, Daniel Paucar, Balazs Halmos

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Non-small-cell lung cancers that harbor activating mutations in the EGFR gene represent an important molecularly defined subset of lung cancer. Despite dramatic initial responses with first- and second-generation EGFR-directed tyrosine-kinase inhibitors (TKIs) against these cancers, the development of a dominant and frequent resistance mechanism through a threonine-methionine amino acid substitution at position 790 (T790M) of EGFR has limited the long-term efficacy of these targeted therapies. This “gatekeeper” EGFR T790M alteration remains the only validated and relevant second-site resistance mutation for EGFR, allowing for focused research to understand and overcome EGFR T790M-mediated resistance. The current review focuses on EGFR T790M by discussing mechanisms of resistance mediated by EGFR T790M, reviewing development of novel third-generation EGFR TKIs targeting EGFR T790M, and highlighting current research on overcoming resistance to third-generation EGFR T790M TKIs.

Original languageEnglish (US)
Pages (from-to)147-159
Number of pages13
JournalLung Cancer: Targets and Therapy
Volume8
DOIs
StatePublished - Oct 9 2017

Fingerprint

Protein-Tyrosine Kinases
erbB-1 Genes
Mutation
Threonine
Amino Acid Substitution
Research
Non-Small Cell Lung Carcinoma
Methionine
Lung Neoplasms
Neoplasms
Therapeutics

Keywords

  • Epidermal growth factor receptor
  • Lung cancer
  • Resistance
  • T790M
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

EGFR T790M : Revealing the secrets of a gatekeeper. / Ko, Brian; Paucar, Daniel; Halmos, Balazs.

In: Lung Cancer: Targets and Therapy, Vol. 8, 09.10.2017, p. 147-159.

Research output: Contribution to journalReview article

@article{b6c5babde28c4877bec22af1e2ce8759,
title = "EGFR T790M: Revealing the secrets of a gatekeeper",
abstract = "Non-small-cell lung cancers that harbor activating mutations in the EGFR gene represent an important molecularly defined subset of lung cancer. Despite dramatic initial responses with first- and second-generation EGFR-directed tyrosine-kinase inhibitors (TKIs) against these cancers, the development of a dominant and frequent resistance mechanism through a threonine-methionine amino acid substitution at position 790 (T790M) of EGFR has limited the long-term efficacy of these targeted therapies. This “gatekeeper” EGFR T790M alteration remains the only validated and relevant second-site resistance mutation for EGFR, allowing for focused research to understand and overcome EGFR T790M-mediated resistance. The current review focuses on EGFR T790M by discussing mechanisms of resistance mediated by EGFR T790M, reviewing development of novel third-generation EGFR TKIs targeting EGFR T790M, and highlighting current research on overcoming resistance to third-generation EGFR T790M TKIs.",
keywords = "Epidermal growth factor receptor, Lung cancer, Resistance, T790M, Targeted therapy",
author = "Brian Ko and Daniel Paucar and Balazs Halmos",
year = "2017",
month = "10",
day = "9",
doi = "10.2147/LCTT.S117944",
language = "English (US)",
volume = "8",
pages = "147--159",
journal = "Lung Cancer: Targets and Therapy",
issn = "1179-2728",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - EGFR T790M

T2 - Revealing the secrets of a gatekeeper

AU - Ko, Brian

AU - Paucar, Daniel

AU - Halmos, Balazs

PY - 2017/10/9

Y1 - 2017/10/9

N2 - Non-small-cell lung cancers that harbor activating mutations in the EGFR gene represent an important molecularly defined subset of lung cancer. Despite dramatic initial responses with first- and second-generation EGFR-directed tyrosine-kinase inhibitors (TKIs) against these cancers, the development of a dominant and frequent resistance mechanism through a threonine-methionine amino acid substitution at position 790 (T790M) of EGFR has limited the long-term efficacy of these targeted therapies. This “gatekeeper” EGFR T790M alteration remains the only validated and relevant second-site resistance mutation for EGFR, allowing for focused research to understand and overcome EGFR T790M-mediated resistance. The current review focuses on EGFR T790M by discussing mechanisms of resistance mediated by EGFR T790M, reviewing development of novel third-generation EGFR TKIs targeting EGFR T790M, and highlighting current research on overcoming resistance to third-generation EGFR T790M TKIs.

AB - Non-small-cell lung cancers that harbor activating mutations in the EGFR gene represent an important molecularly defined subset of lung cancer. Despite dramatic initial responses with first- and second-generation EGFR-directed tyrosine-kinase inhibitors (TKIs) against these cancers, the development of a dominant and frequent resistance mechanism through a threonine-methionine amino acid substitution at position 790 (T790M) of EGFR has limited the long-term efficacy of these targeted therapies. This “gatekeeper” EGFR T790M alteration remains the only validated and relevant second-site resistance mutation for EGFR, allowing for focused research to understand and overcome EGFR T790M-mediated resistance. The current review focuses on EGFR T790M by discussing mechanisms of resistance mediated by EGFR T790M, reviewing development of novel third-generation EGFR TKIs targeting EGFR T790M, and highlighting current research on overcoming resistance to third-generation EGFR T790M TKIs.

KW - Epidermal growth factor receptor

KW - Lung cancer

KW - Resistance

KW - T790M

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85032827360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032827360&partnerID=8YFLogxK

U2 - 10.2147/LCTT.S117944

DO - 10.2147/LCTT.S117944

M3 - Review article

AN - SCOPUS:85032827360

VL - 8

SP - 147

EP - 159

JO - Lung Cancer: Targets and Therapy

JF - Lung Cancer: Targets and Therapy

SN - 1179-2728

ER -